Revance Therapeutics Inc (RVNC) concluded trading on Thursday at a closing price of $3.07, with 3.97 million shares of worth about $12.18 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 15.41% during that period and on December 19, 2024 the price remained unchanged. Currently the company’s common shares owned by public are about 104.90M shares, out of which, 95.30M shares are available for trading.
Stock saw a price change of -0.65% in past 5 days and over the past one month there was a price change of -18.35%. Year-to-date (YTD), RVNC shares are showing a performance of -65.07% which decreased to -62.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.30 but also hit the highest price of $9.74 during that period. The average intraday trading volume for Revance Therapeutics Inc shares is 2.70 million. The stock is currently trading -12.19% below its 20-day simple moving average (SMA20), while that difference is down -30.43% for SMA50 and it goes to -29.92% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Revance Therapeutics Inc (NASDAQ: RVNC) currently have 104.90M outstanding shares and institutions hold larger chunk of about 80.74% of that.
The stock has a current market capitalization of $320.48M and its 3Y-monthly beta is at 0.86. It has posted earnings per share of -$1.92 in the same period. It has Quick Ratio of 3.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RVNC, volatility over the week remained 0.66% while standing at 4.38% over the month.
Stock’s fiscal year EPS is expected to rise by 42.40% while it is estimated to increase by 38.87% in next year. EPS is likely to grow at an annualized rate of 11.60% for next 5-years, compared to annual growth of 0.57% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on January 29, 2024 offering a Neutral rating for the stock and assigned a target price range of between $16 and $9 to it. Coverage by Goldman stated Revance Therapeutics Inc (RVNC) stock as a Neutral in their note to investors on January 09, 2024, suggesting a price target of $8 for the stock. On August 16, 2023, Exane BNP Paribas Upgrade their recommendations, while on October 11, 2022, Morgan Stanley Initiated their ratings for the stock with a price target of $27. Stock get a Buy rating from Goldman on September 22, 2022.
